Abstract

BackgroundAntibiotic dosing in neonates varies between countries and centres, suggesting suboptimal exposures for some neonates. We aimed to describe variations and factors influencing the variability in the dosing of frequently used antibiotics in European NICUs to help define strategies for improvement.MethodsA sub-analysis of the European Study of Neonatal Exposure to Excipients point prevalence study was undertaken. Demographic data of neonates receiving any antibiotic on the study day within one of three two-week periods from January to June 2012, the dose, dosing interval and route of administration of each prescription were recorded. The British National Formulary for Children (BNFC) and Neofax were used as reference sources. Risk factors for deviations exceeding ±25% of the relevant BNFC dosage recommendation were identified by multivariate logistic regression analysis.ResultsIn 89 NICUs from 21 countries, 586 antibiotic prescriptions for 342 infants were reported. The twelve most frequently used antibiotics – gentamicin, penicillin G, ampicillin, vancomycin, amikacin, cefotaxime, ceftazidime, meropenem, amoxicillin, metronidazole, teicoplanin and flucloxacillin – covered 92% of systemic prescriptions. Glycopeptide class, GA <32 weeks, 5th minute Apgar score <5 and geographical region were associated with deviation from the BNFC dosage recommendation. While the doses of penicillins exceeded recommendations, antibiotics with safety concerns followed (gentamicin) or were dosed below (vancomycin) recommendations.ConclusionsThe current lack of compliance with existing dosing recommendations for neonates needs to be overcome through the conduct of well-designed clinical trials with a limited number of antibiotics to define pharmacokinetics/pharmacodynamics, efficacy and safety in this population and by efficient dissemination of the results.Electronic supplementary materialThe online version of this article (doi:10.1186/s12887-015-0359-y) contains supplementary material, which is available to authorized users.

Highlights

  • Antibiotic dosing in neonates varies between countries and centres, suggesting suboptimal exposures for some neonates

  • In the dosing analysis further grouping by postmenstrual age (PMA) or postnatal age (PNA) was based on the recommendations for the respective antibiotic in the chosen dosing references (Tables 1, 2)

  • Clinicians’ and experts’ distrust of newer dosing recommendations needs to be overcome by adequate clinical trials to support PK/PD, efficacy and safety

Read more

Summary

Introduction

Antibiotic dosing in neonates varies between countries and centres, suggesting suboptimal exposures for some neonates. We aimed to describe variations and factors influencing the variability in the dosing of frequently used antibiotics in European NICUs to help define strategies for improvement. While some questionnaire-based studies of neonatal antibiotic doses suggest compliance with existing dosing recommendations, others, including unpublished data from the Antimicrobial Resistance and Prescribing in European Children (ARPEC) point prevalence study (PPS), have highlighted large variations in dosing regimens of many commonly used antibiotics in neonates [6,7,8]. Unexplained dosing variability is a marker of suboptimal patient management meaning that some babies are under- while others are over-dosed. This raises a number of questions about how to deliver optimal dosage of antibiotics to neonates. Should efforts to disseminate existing evidence be improved?

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call